TDN345 A 是一種 <b>Ca<sup>2+</sup></b> 拮抗劑,主要用于治療血管和老年癡呆疾病,例如阿爾茨海默癥。<BR><a href="https://www.medchemexpress.cn/EPZ015866.html">EPZ015866</a>產(chǎn)品描述:EPZ015866 (GSK591) is a potent selective inhibitor of the arginine methyltransferase PRMT5. It maintained excellent selectivity against other PMT enzymes observed with EPZ015666 [1].IC50:61 nM-904 nM in Maver-1 cells [2]target: PRMT5in vitro: A375 cells treated for 18 h with 1 μM EPZ015666 showed stabilization of PRMT5 in cellular thermal shift analysis in whole-cell lysates. [2]In vivo: EPZ015666 or vehicle (0.5% methylcellulose in water) was administered orally BID at a dose volume of 10 mL/kg for 21 d (Granta-519 was dosed for 18 d). [2]<br><br><br><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設(shè)有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網(wǎng)點遍及全球20多個國家地區(qū)。MCE經(jīng)過多年努力已成為全球生物活性小分子領(lǐng)域的一流供應(yīng)商, 產(chǎn)品涵蓋癌癥、神經(jīng)科學(xué)、抗感染、表觀遺傳學(xué)等20個熱門研究領(lǐng)域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現(xiàn)貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務(wù)。</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 對每批產(chǎn)品都進行嚴格的LCMS和NMR檢驗,其產(chǎn)品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各領(lǐng)域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">數(shù)千種產(chǎn)品在上海有充足備貨,24-48小時內(nèi)送達客戶;</span><br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量產(chǎn)品提供免費試用裝;</span><span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">已為全球多個知名企業(yè)、院校構(gòu)建各種定制型化合物庫。</span><br><br>產(chǎn)品鏈接:<a href="http://www.medchemexpress.cn/EPZ015866.html">www.medchemexpress.cn/EPZ015866.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt="">Purity:98%<BR>MWt:468.5786<BR>Formula:C28H34F2N2O2<BR>SMILES:O=C(N1C(C)(C)C)OC2(CCN(CCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)C1=C<BR>Pathway:Membrane Transporter/Ion Channel; <BR>Mechanisms:Calcium Channel; <BR>Research Area:Neurological Disease<BR>電話: 021-58955995<BR>網(wǎng)址: www.MedChemExpress.cn <BR>地址: 上海市浦東新區(qū)蔡倫路720號2號樓3層 |
TDN345前沿研究進展
發(fā)布日期:2017-11-13 瀏覽次數(shù):0
核心提示:TDN345 A 是一種 bCasup2+/sup/b 拮抗劑,主要用于治療血管和老年癡呆疾病,例如阿爾茨海默癥。BRa href=https://www.medchemexp
- 下一篇:暫無
- 上一篇:Sulamserod前沿研究進展
行業(yè)動態(tài)
更多...
- TDN345前沿研究進展 11-13
- Sulamserod前沿研究進展 11-13
- Win 58237前沿研究進展 11-13
- Nifursemizone前沿研究進 11-13
- Pargolol (hydrochloride) 11-13
- COX2-IN-1前沿研究進展 11-13
- MHP 133前沿研究進展 11-13
- WQ 2743前沿研究進展 11-13
- Imiglitazar前沿研究進展 11-13
- ACAT-IN-1 cis isomer前沿 11-13